A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Recruiting now · Phase 1/Phase 2
Conditions studied: Overweight and Obesity
In brief
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.
Key facts
- Study ID
- NCT06842186
- Run by
- Wave Life Sciences USA, Inc.
- People needed
- 296
- Starts
- 2025-01-31
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- Parexel International-EPCU Baltimore — Baltimore, Maryland, United States (enrolling)
- ARENSIA Research Clinic — Chisinau, Moldova (enrolling)
- Arensia Clinics S.R.L. — Bucharest, Romania (enrolling)
- Spitalul Clinic Judetean De Urgenta Cluj — Cluj-Napoca, Romania (enrolling)
- Parexel International Early Phase Clinical Unit — Harrow, United Kingdom (enrolling)
- Simbec-Orion Clinical Pharmacology — Merthyr Tydfil, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.